Background: Low bone mineral density (BMD) is a significant comorbidity in HIV. However, studies evaluating vitamin D supplementation on bone health in this population are limited. This study investigates changes in bone health parameters after 12 months of supplementation in HIV-infected youth with vitamin D insufficiency.
INTRODUCTION
People with HIV are living longer than ever before because of combination antiretroviral therapy (cART). In fact, life expectancy nears that of the general population in developed countries. 1 However, HIV-infected patients are experiencing more medical comorbidities, such as osteoporosis and fractures, compared with age-matched individuals in the general population. 2 The cause of bone loss in HIV is multifactorial, including traditional risk factors and alterations in bone metabolism due to a direct effect of antiretrovirals (ARVs) or of HIV viral proteins, and the chronic inflammatory state associated with HIV. 3 Low bone mineral density (BMD) and osteoporosis are also much more common among HIV-infected children and young adults than their counterparts in the general population, regardless of whether HIV is acquired perinatally or later in adolescence. [4] [5] [6] Likewise, there are some, albeit sparse, data suggesting that they may be at an increased risk of fractures too. 7 In fact, bone toxicity is especially concerning in this younger population, as the majority of bone mass acquisition occurs during this period of rapid growth, and the effects of chronic HIV infection and exposure to cART accumulate over many decades. The long-term ramifications of these alterations in bone metabolism and reductions in BMD as this younger population ages are particularly alarming.
Vitamin D is essential for optimal bone health; however, the extent to which vitamin D deficiency contributes to bone disease in HIV is largely unknown. By contrast, in the general population, there are data from randomized-controlled trials (RCTs) showing that vitamin D supplementation improves BMD and modestly decreases the risk of fracture. [8] [9] [10] Even in healthy children, vitamin D supplementation, particularly among those with vitamin D deficiency, shows promise in improving BMD. 11, 12 However, there are only a few published RCTs investigating vitamin D supplementation trials for improved bone health in the adult HIV population 13 and HIV-infected youth population, 14, 15 and results have been conflicting.
Exploring vitamin D supplementation may be even more important in HIV as a way of mitigating bone disease, given that some of the bone disease in HIV seems to be related to the associated chronic inflammation and heightened immune response. In addition to its role in bone health, vitamin D has wide-reaching immunomodulatory effects and plays a critical role in immune function including promoting an anti-inflammatory state. [16] [17] [18] [19] Vitamin D insufficiency is widespread in the HIV population, [20] [21] [22] providing even more support that additional RCTs investigating the effect of vitamin D supplementation on bone in this population are urgently needed.
In this current analysis, we sought to explore the effects of vitamin D supplementation on bone health parameters in HIVinfected children and young adults with vitamin D insufficiency in the context of an RCT. Our focus on HIV-infected youth represents an innovative approach to potentially identify efficacious strategies to prevent the development of HIV-related bone disease before the onset of clinical symptoms.
METHODS

Study Design/Population
This is a randomized, active-control, double-blind, 24-month trial designed to measure the effect of vitamin D supplementation in HIV-1-infected youth. Subjects were recruited from the HIV clinics of University Hospitals Cleveland Medical Center, Cleveland, OH and Grady Health System, Atlanta, GA through electronic medical record system queries and case manager/provider referrals. Subjects were eligible if they were between 8 and 25 years of age with documented HIV-1 infection on a stable cART regimen for $12 weeks, with $6 months of cumulative cART duration, HIV-1 RNA level ,1000 copies/mL, with no intent to change cART regimen, diet, sun exposure, or exercise routine during the study period, and a baseline serum 25- 24 The randomization scheme was computer generated, stratified by efavirenz (EFV) use at entry (an ARV drug that has been shown to affect 25(OH)D concentrations in some studies 25 ) , and provided by investigational pharmacist departments at each site. Each vitamin D 3 capsule contained either 9000, 30,000, or 60,000 IU. Each dose consisted of 2 capsules so that the amount of vitamin D 3 totaled the appropriate dose for the subject's randomized arm (eg, subjects in the standard-dose arm took two 9000 IU capsules so that the total was 18,000 IU). Regardless of dose, all capsules look identical. All subjects took 2 capsules at baseline and then monthly after being prompted by a reminder phone call from study staff. Subjects returned for study visits every 3 months. Representative capsules were sent to an independent laboratory (Analytical Research Laboratories, Oklahoma City, OK) at regular intervals during the study period to ensure continued potency of each vitamin D dose.
The study was reviewed and approved by the Institutional Review Boards of University Hospital Case Medical Center, Emory University and Grady Health System. Parents or legal guardians provided written informed consent for minors, and patients $18 years of age signed their own informed consent. The study was registered on clinicaltrials. gov (NCT01523496).
Here, we present the prespecified secondary analysis that assessed changes in BMD and bone turnover markers from baseline to 12 months in HIV-infected subjects.
Clinical Assessments
Relevant data were obtained by questionnaire, including demographics, current and past medical history, alcohol intake, tobacco use, and drug habits. Further information was collected from the HIV-infected subjects' medical records, including past and current medical diagnoses, nadir CD4 count, detailed past and current ARV and non-ARV medication use, HIV diagnosis date, and acquisition method (perinatal or horizontal). Targeted physical examination and weight and height measurements were obtained.
Laboratory Assessments
Blood was collected from all participants after at least an 8-hour fast. Serum concentrations of 25(OH)D were measured as the best measure of overall vitamin D status. 26 Serum 25(OH)D concentrations were measured using either an automated chemiluminescent technique (IDS-iSYS automated machine; Immunodiagnostic Systems, Inc., Fountain Hills, AZ) or a competitive immunoassay (ADVIA Centaur XP System, Siemens Healthcare Diagnostics, Inc., Tarrytown, NY). Parathyroid hormone was measured using enzyme-linked immunosorbent assay (Immutopics, Inc., Athens, OH).
Plasma bone turnover markers were also measured, including the bone formation markers, osteocalcin (OC) and procollagen type 1 aminoterminal propeptide (P1NP), and the bone resorption marker, Β-CrossLaps (Β-CTx). OC and BCTx were measured using a sandwich immunoassay on the Roche Elecsys 2010 (Roche Diagnostics, Indianapolis, IN). Median interassay coefficients of variance for OC and Β-CTx were 5.15%-9.40% and 4.13%-5.82%, respectively. P1NP was measured using a radioimmunoassay (Immunodiagnostics Systems, Fountain Hills, AZ), and the median interassay coefficient of variance was 5.86%-15.44%.
Absolute CD4 + T-cell count and plasma HIV-1 RNA level were concomitantly measured as markers of HIV disease activity. Because there were several different assays used in the clinical laboratories of the 2 study sites to measure HIV-1 RNA levels, there were varying lower limits of detection (,20, ,40, ,48, ,79, and ,80 copies/mL) used throughout the study. Less than 80 copies/mL was the highest cutoff that defined an undetectable HIV-1 RNA; thus, we considered any HIV-1 RNA ,80 copies/mL as undetectable.
BMD Assessments
Lumbar spine and total hip BMD were assessed using dual-energy x-ray absorptiometry at baseline and 12 months. Measurements were obtained for individual subjects on the same scanner at both time points (GE Lunar Prodigy, GE Healthcare). The left hip was used in all cases, unless clinically contraindicated, and only the total hip BMD was used as the hip BMD of interest. Lumbar spine BMD was measured at L1-L4.
Statistical Analyses
Analyses were performed using intent-to-treat principles based on randomized treatment assignment which used all available data, and missing data were ignored.
First, BMD data from the moderate-and high-dose arms were compared. It was determined in preliminary analyses that there was no significant difference in the % change for spine or total hip BMD over the study period (see Results section). Thus, the subjects randomized to receive the moderate or high doses were considered together (supplementation arm) and compared with subjects randomized to receive the standard dose (active control).
Nominal variables were compared using x 2 analysis or the Fisher exact test as appropriate. Continuous measures were tested for normality. For between-group comparisons (baseline and changes from baseline to 12 months), normally distributed variables were compared using the t test, and nonnormally distributed variables were compared using the Wilcoxon rank-sum test. For within-group changes from baseline to 12 months, normally distributed variables were assessed with the paired t test, and nonnormally distributed variables were assessed with the Wilcoxon signed-rank test. Spearman correlation coefficients were used to investigate associations between changes in bone parameters and variables of interest.
Additional analyses were conducted to further assess changes in serum 25(OH)D concentrations, BMD, and bone turnover markers for the 3 dosing groups separately (standard, moderate, and high). The Kruskal-Wallis test was used to compare differences in changes in the bone turnover markers over the 12-month time period among the 3 groups. Linear regression models were then used to compare the changes in bone turnover markers for the 3 groups while adjusting for potential confounders. Confounding variables were chosen based on clinical importance and included race, sex, and the following baseline characteristics: age, body mass index (BMI), Tanner stage (5 vs. ,5), and HIV-1 RNA (,80 vs. $80 copies/mL).
All statistical tests were 2 sided with a 0.05 significance level. Analyses were performed with SAS version 9.4 (SAS Institute, Cary, NC).
RESULTS
Baseline Characteristics
Subjects were recruited from January 2012 to July 2014. One hundred two HIV-infected subjects were enrolled in the study; 81 subjects completed their 12-month visit (Fig.  1) . Of those 81 subjects, 30, 24, and 27 were in the standard-, moderate-, and high-dose groups, respectively.
As described in the methods, there was no significant difference between % change in spine or hip BMD over the study period between the moderate-and high-dose arms [median (quartile 1, quartile 3) % change in spine and hip BMD, respectively: moderate-dose arm = +3.6 (+0.3, +9.2) and +1.8 (21.2, +4.3), high-dose arm = +2.1 (20.1, +5.9) and +0.4 (20.5, +2.5); P = 0.28 (spine) and P = 0.61 (hip)]. Thus, subjects from the moderate-and high-dose arms were combined into 1 group (supplementation arm) and compared with subjects in the standard-dose arm (active control).
Baseline characteristics are shown in Table 1 . Overall, there was a median age of 20 years with 64% male and 89% black. Fifty-six subjects were on a ritonavir-boosted protease inhibitor (PI/r) (darunavir = 29; atazanavir = 20; and lopinavir = 7), 39 subjects were on a nonnucleoside reverse transcriptase inhibitor (EFV = 27; rilpivirine = 9; nevirapine = 2; and etravirine = 1), and 9 subjects were on an integrase inhibitor (elvitegravir/cobicistat = 7; dolutegravir = 1; and raltegravir = 1). Nucleoside reverse transcriptase inhibitor backbones included emtricitabine/tenofovir (N = 91), lamivudine/abacavir (N = 7), lamivudine/zidovudine (N = 2), stavudine/abacavir (N = 1), and lamivudine/zidovudine/abacavir (N = 1).
At baseline, study arms were well matched for most variables, except that there were statistically more smokers in the supplementation arm than the standard arm, and the hip zscore was statistically lower in the standard arm than the supplementation arm.
Changes in Clinical Characteristics
The time that elapsed from the baseline visit to the 12-month visit was similar for all study arms [mean (SD) number of days between study visits: standard-dose arm = 366.1 (19.5) Thirteen subjects who were still in the study at the 12-month time point changed their ART regimens, reflecting in part updates to the Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. 27 Seven subjects (3 in supplementation arm and 4 in standard arm) switched a PI/r to rilpivirine (N = 1), elvitegravir/cobicistat (N = 5), or dolutegravir (N = 1). Five subjects (2 in supplementation arm and 3 in standard arm) switched from EFV to rilpivirine (N = 1), elvitegravir/cobicistat (N = 2), or dolutegravir (N = 1). One of these subjects (from the supplementation arm) stopped ARVs completely. One additional subject on a PI/r switched to EFV for a short period and then switched back to a PI/r. Other than the subject who stopped ARVs, no subject changed nucleoside reverse transcriptase inhibitors. Overall, 88% of subjects maintained an HIV-1 RNA ,1000 copies/mL throughout the 12-month study period (86% in supplementation arm and 90% in standard arm).
There was no difference between the supplementation arm vs. standard arm at 12 months for current CD4 count (712 vs. 665 cells/mm 3 ; P = 0.91), % of subjects with HIV-1 RNA ,80 copies/mL (78% vs. 90%; P = 0.88), or % of subjects at Tanner stage 5 (82% vs. 76%; P = 0.57). BMI was significantly higher in the supplementation arm when compared with the standard arm (23.8 vs. 21.3 kg/m 2 , P = 0.02).
Changes in Serum 25(OH)D Concentrations
Overall, 25(OH)D concentrations increased significantly over the 12-month study period for all study arms (Table 2) , although the increase was greater in the supplementation arm.
In the supplementation arm, 71% and 90% of subjects maintained a serum 25(OH)D concentration $30 and $20 ng/mL, respectively, at every measured time point (3, 6, 9, and 12 months) compared with 33% and 67%, respectively, in the standard arm. Similarly, 80% and 90% of subjects had a serum 25(OH)D concentration $30 and $20 ng/mL, respectively, at the 12-month time point compared with 63% and 80%, respectively, in the standard arm.
Within the supplementation arm, 54% and 88% in the moderate-dose group and 85% and 93% in the high-dose group maintained a serum 25(OH)D concentration $30 and $20 ng/mL, respectively, at every measured time point. At the 12-month time point, 71% and 88% in the moderate-dose group and 89% and 93% in the high-dose group had a serum 25(OH)D concentration $30 and $20 ng/mL, respectively. FIGURE 1. Consort diagram of study participants. One hundred seventy patients were screened for enrollment. Sixty-eight subjects' screen failed, resulting in 102 subjects enrolled. Twenty-one subjects were withdrawn before their 12-month study visit, leaving 81 subjects. PI, principal investigator.
Through the 12-month time point, there were no studyrelated adverse events, interruptions in study drug administration, or known nonadherence for any subject in any dosing group. No subject achieved a serum 25(OH)D concentration $100 ng/mL. There was 1 subject who reported mild nausea after taking the cholecalciferol capsules; this subject withdrew from the study before the 12-month time point for nonstudyrelated reasons. Table 2 depicts the changes in bone endpoints. For the HIV-infected subjects combined, % change in spine BMD and spine z-score increased significantly. There was a trend toward a significant increase in % change in hip BMD but not for the hip z-score. All 3 bone turnover markers decreased significantly.
Changes in Bone Parameters
In the supplementation arm, % change in spine and hip BMD and spine z-score increased significantly. In the standard arm, only % change in hip BMD increased significantly. All 3 bone turnover markers decreased significantly within the supplementation arm, without significant changes in the standard arm.
Changes in bone turnover markers were then further analyzed for the 3 dosing arms separately (standard, moderate, and high). Only the high-dose arm showed significant decreases for both P1NP (P = 0.001) and Β-CTx (P = 0.0005) (Table 3; Figure 2 in Supplemental Digital Content, http://links.lww.com/QAI/B81). These changes were statistically significantly different among the 3 groups for P1NP (P = 0.038) and approached significance for Β-CTx (P = 0.07). Changes in P1NP and Β-CTx were then compared among the 3 groups after adjusting for potential confounders (race, sex, and baseline age, BMI, Tanner stage, and HIV-1 RNA). The high-dose arm had statistically significant decreases in P1NP compared with the standard-dose arm (P = 0.02), and differences in B-CTx changes approached significance (P = 0.07) (Figure 2 in Supplemental Digital Content, http://links.lww.com/QAI/B81).
There were no significant differences between % change in spine and hip BMD between the standard arm 
Correlations
There were no significant correlations between % change in spine BMD and either baseline or changes in serum 25(OH)D concentrations. There was a significant negative correlation between % changes in spine BMD and changes in plasma OC (R = 20.36; P = 0.0019), but not plasma B-CTx or P1NP. None of the above correlations were significant when % change in hip BMD was considered; however, there was a trend toward an inverse significant relationship with changes in OC (% change: R = 20.19; P = 0.0998). Changes in 25(OH)D were not significantly correlated with changes in any of the bone turnover markers.
DISCUSSION
In this current study, we investigated the effects of vitamin D supplementation on BMD and bone markers after 12 months of monthly oral vitamin D 3 in HIV-infected youth on cART with vitamin D insufficiency. Serum 25(OH)D concentrations increased significantly after 12 months with all 3 doses [18,000 IU/mo (standard/active-control dose), 60,000 IU/mo (moderate dose), and 120,000 IU/mo (high dose)]; however, serum 25(OH)D concentrations increased significantly more in the supplementation arm (moderate and high doses) compared with the standard arm. Notably, the high dose within the supplementation arm (ie, 120,000 IU/ monthly) maintained serum 25(OH)D concentrations in the optimal range more consistently throughout the study period than either the moderate or standard doses. And, perhaps most importantly, the standard vitamin D dose (600 IU/d; given in this study as 18,000 IU/mo) recommended by the IOM to satisfy the vitamin D requirements of 97.5% of healthy individuals (to maintain a serum 25(OH)D concentration $20 ng/mL) was insufficient for more than one-third of the subjects randomized to that arm. Likewise, the IOM's upper tolerable limit of 4000 IU/d (given in this study as 120,000 IU/mo) satisfied the vitamin D requirements of 93% of subjects randomized to that dose. Notably, bone turnover markers decreased significantly more in the supplementation arm (compared with the standard arm), and the decrease was more pronounced with the high dose. However, no significant differences in BMD changes were detected between groups. ‡P value for changes within group. §P value for differences in changes between the 2 dosing arms. kThe upper limit of detection for P1NP was 300 ng/mL. At the 12-month time point, 11.8% and 23.3% of subjects in the supplementation and standard arms, respectively, had unmeasurable values above the upper limit and were assigned a value of 300 ng/mL for the purpose of calculation of change from baseline.
Bold-faced P values indicate those ,0.05. PTH, parathyroid hormone; Q, quartile. kP value for differences in changes among the 3 dosing groups. ¶The upper limit of detection for P1NP was 300 ng/mL, and those subjects with an unmeasurable value above the upper limit were assigned a value of 300 ng/mL for the purpose of calculation of change from baseline.
Bold-faced P values indicate those ,0.05. Q, quartile.
Overall, both study arms showed some increases in BMD over the study period, as expected given that some of our population was still growing. And, despite some suggestive data, we were unable to conclusively demonstrate that vitamin D supplementation was related to those improvements. This may merely be a reflection of inadequate sample size and/or insufficient follow-up time to show differences in BMD among the 3 different doses and/or a lack of a true placebo. In support of this, we observed significant decreases in bone turnover markers within the high-dose arm not seen in the other 2 dosing arms, with changes in P1NP being the most dramatic. This finding has also been reported in a recent abstract of an open-label study of vitamin D supplementation in HIV-infected youth, 28 and it may reflect an early, beneficial effect of high-dose vitamin D on bone health in HIV before significant changes are observed in BMD.
Bone undergoes constant remodeling with osteoclasts resorbing older bone and osteoblasts laying down new bone, and the actions of osteoclasts and osteoblasts can be assessed in vivo using markers of bone turnover. This process is normally tightly coupled, but in HIV and especially with cART-initiation, accelerated bone resorption and an increased bone formation result in a net loss of bone. 29, 30 It is not clear, however, whether these changes result from alterations in the inflammatory/immune environment, direct ARV effects, or a combination of factors. Indeed, bone metabolism is also mediated in part by inflammatory cytokines that affect the activity of osteoclasts and osteoblasts. 31 Given the chronic inflammatory state associated with HIV and known immunomodulatory effects of vitamin D, further studies are needed to investigate the mechanisms and the clinical consequences of the changes that we and others have observed in bone turnover markers with vitamin D supplementation.
It is also important to note that our study design used an active-control arm instead of a true placebo which likely blunted our ability to detect differences in BMD changes among the dosing arms. However, because of ethical concerns about failing to treat subjects with vitamin D insufficiency/deficiency, we chose not to have a true control/placebo arm. Likewise, we used a bolus dosing strategy designed to minimize additional pill burden, given the risk of poor adherence to medication among adolescents and young adults. Serum 25(OH)D, the major circulating form of vitamin D and the metabolite most commonly used to assess overall vitamin D status, has a long half-life of ;15 days, 32 theoretically allowing a longer interval between vitamin D doses. Yet, some data suggest that a daily dosing schedule exerts superior therapeutic effects compared with large bolus doses, which can result in both a steep and rapid increase in circulating 25(OH)D concentrations, followed by a slow decline. 33 Thus, although bolus dosing strategies are particularly appealing in this population who often struggle with adherence to daily medications, daily dosing may be necessary to achieve clinically meaningful benefits from vitamin D supplementation.
However, a recent abstract describing a study using daily vitamin D in adults with HIV also failed to demonstrate any clear benefit on BMD. 34 One commonality may not be the dosing schedule per se, but instead whether the dose results in a sustained elevation of serum 25(OH)D concentrations in an optimal range. Importantly, in our study, we demonstrated that a higher dose of vitamin D is needed to maintain 25(OH)D at sufficient serum concentrations based on either the IOM's ($20 ng/mL) or Endocrine Society's ($30 ng/mL) current recommendations and that the current IOM recommended dose (600 IU/daily) is not enough. In fact, these findings alone are important to help inform future trials.
Our study suffered from some limitations worth mentioning. As previously discussed, there was a relatively small sample size and a lack of a true placebo arm which limited the conclusions we could make. Moreover, the correlations we observed among serum 25(OH)D concentrations, BMD, and bone turnover markers, in particular, should be interpreted with caution, given the small study population with frequent ART changes. In addition, a 1-year follow-up period may not be long enough to assess changes in BMD. Furthermore, our study lacked adherence measurements to study drug, such as pill counts, although limitations of adherence assessments are well recognized. Finally, the majority of our study population was African American, and the correlation between serum 25(OH)D concentrations and bone health has been questioned. 35 As such, in this mostly African American population, serum 25(OH)D concentrations may not be reflective of vitamin D status or free vitamin D concentrations.
In conclusion, we showed that high-dose vitamin D supplementation (120,000 IU/mo) decreases bone turnover markers, which may reflect an early, beneficial effect on bone health in HIV that could result in clinically meaningful changes over time. Likewise, a higher dose of vitamin D supplementation is needed to achieve optimal 25(OH)D concentrations for this population. Our study underscores the complicated nature of bone disease in HIV-infected youth and the potential impact of chronic HIV and cART exposure that will span many decades. Further studies investigating how vitamin D supplementation affects BMD and bone microarchitecture in this vulnerable population are urgently needed.
